Posters presented at the 2026 AAD Annual Meeting examined bimekizumab for hidradenitis suppurative across various subgroups ...

Adults with moderate to severe hidradenitis suppurativa experienced substantial long-term symptom relief and quality of life ...

Povorcitinib, an oral JAK-1 inhibitor currently being investigated for hidradenitis suppurativa, demonstrated substantial ...

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting ...

Incyte’s phase 3 STOP-HS data show that povorcitinib improved symptoms of moderate to severe hidradenitis suppurativa in most ...

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses ...

Screening for insulin resistance early after the diagnosis of hidradenitis suppurativa shows promise for guiding therapies to improve the disease course.

UCB, a global biopharmaceutical company, today announced data for BIMZELX in active moderate-to-severe hidradenitis suppurativa (HS) at the 2026 American Academy of Dermatology (AAD) Annual Meeting in ...

First Patient Dosed (FPD) in Phase 2a MAINSAIL Trial of NAV-240 in Hidradenitis Suppurativa (HS)Phase 1b Multiple Ascending ...

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated ...

CONTINUOUS secukinumab treatment showed sustained hidradenitis suppurativa lesion control through 4 years in responding patients. Sustained Lesion Improvements with Secukinumab. N ...

New findings have been presented on a couple of late-stage candidates in hidradenitis suppurativa (HS) at the 2026 American ...